Skip to main content
logo
Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
18.55
-1.42 (-7.11%)
May 18, 2026, 4:00 PM EDT - Market closed

Crescent Biopharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Cap
6163272515216575
Market Cap Growth
-1188.57%-83.31%-7.77%118.72%-59.13%
Enterprise Value
428.78118.8432.08110.18116.89-14.92
Last Close Price
18.5511.8624.90236.00303.00144.00
PE Ratio
--0.93-0.42-4.07-3.40-1.17
PS Ratio
51.8730.14-15196.902196.8664.95
PB Ratio
3.4381.1425363.20---
P/TBV Ratio
81.7030.6616054.88---
P/FCF Ratio
--4.51-4.05-4.35-3.54-1.31
P/OCF Ratio
--4.57-4.05-4.36-3.55-1.31
EV/Sales Ratio
36.0810.96-11017.601558.58-12.87
EV/EBITDA Ratio
--0.78-0.80-2.82-2.480.24
EV/EBIT Ratio
--0.78-0.80-2.81-2.470.24
EV/FCF Ratio
--1.64-5.12-3.16-2.510.26
Debt / Equity Ratio
0.010.01-2.42000
Debt / EBITDA Ratio
-0.01-0.01-0.94-0.02-0.02-0.02
Debt / FCF Ratio
-0.02-0.02-5.98-0.02-0.02-0.02
Net Debt / Equity Ratio
-46.58-52.522716.00---
Net Debt / EBITDA Ratio
1.151.39-0.071.051.001.41
Net Debt / FCF Ratio
2.462.92-0.431.181.011.55
Asset Turnover
0.050.0800.000.000.01
Quick Ratio
13.336.413.626.115.397.63
Current Ratio
13.786.563.626.415.717.68
Return on Equity (ROE)
-85.57%-167.78%-330.33%-90.78%-75.05%-60.49%
Return on Assets (ROA)
-74.25%-110.64%-98.94%-80.87%-64.87%-53.50%
Return on Invested Capital (ROIC)
-6572.76%3777.08%710.42%1191.56%881.64%1018.10%
Return on Capital Employed (ROCE)
-83.84%-132.59%-124.18%-96.49%-75.57%-59.60%
Earnings Yield
-26.29%-108.01%-236.95%-24.58%-29.37%-85.42%
FCF Yield
-11.47%-22.17%-24.72%-22.97%-28.25%-76.33%
Buyback Yield / Dilution
--1515.08%-1.79%-20.58%-2.10%-12.54%
Total Shareholder Return
--1515.08%-1.79%-20.58%-2.10%-12.54%
Updated Apr 29, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q